{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:52:16Z","timestamp":1790704336154,"version":"4.1.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pembrolizumab-induced type 1 diabetes mellitus (T1DM) is an uncommon but potentially life-threatening immune-related adverse event. Its clinical course is often abrupt, and evidence regarding its presentation, management, and long-term outcome remains largely derived from isolated case reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Published case reports and case series describing pembrolizumab-induced T1DM were retrieved from PubMed, Embase, Web of Science, CNKI, and Wanfang Data from database inception to June 30, 2026, and retrospectively reviewed. Patient demographics, pembrolizumab exposure, clinical manifestations, laboratory findings, treatments, and outcomes were extracted and analyzed descriptively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>40 eligible articles identified 43 patients. The median age was 67 years (range, 12\u201387), and 24 patients (55.8%) were male. The median interval from pembrolizumab initiation to T1DM onset was 15 weeks (range, 3\u2013104). Melanoma (34.9%) and lung cancer (23.3%) were the most common underlying malignancies, and 35 of 42 patients (83.3%) had no pre-existing diabetes. The predominant symptoms were fatigue or malaise (62.5%), polyuria, polydipsia, or thirst (57.5%), and nausea or vomiting (45.0%). Diabetic ketoacidosis occurred in 36 patients (83.7%). The median blood glucose level at presentation was 558 mg\/dL (range, 277\u20131256), and the median HbA1c was 8.3% (range, 4.6\u201311.4). C-peptide was low in 30 of 34 patients (88.2%), whereas islet autoantibodies were detected in only 15 of 39 patients (38.5%). All patients required insulin therapy, and 27 (62.8%) received fluid or electrolyte replacement. Among 33 patients with available follow-up data, 32 (97.0%) had persistent insulin dependence or \u03b2-cell deficiency. Pembrolizumab was continued or restarted in 13 of 33 patients (39.4%); recurrent diabetic ketoacidosis was reported in one of these 13 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pembrolizumab-induced T1DM is characterized by rapid and usually irreversible \u03b2-cell failure, frequent diabetic ketoacidosis, and persistent insulin dependence. Negative islet autoantibodies do not exclude the diagnosis. Glucose monitoring and prompt assessment of hyperglycemic symptoms are essential during and after treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1947327","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:26:22Z","timestamp":1788236782000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Pembrolizumab-induced type-1 diabetes mellitus: clinical characteristics, therapeutic strategies, and prognosis from a retrospective analysis of 43 published cases"],"prefix":"10.3389","volume":"17","author":[{"given":"Jincai","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Changsha Stomatological Hospital","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiang","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, The Central Hospital of Xiangtan (The affiliated hospital of Hunan university)","place":["Xiangtan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, The Central Hospital of Xiangtan (The affiliated hospital of Hunan university)","place":["Xiangtan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Changsha Stomatological Hospital","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, Pd-L1-positive, advanced non-small-cell lung cancer (Keynote-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2023.0072","article-title":"Immune-checkpoint inhibitors-induced type 1 diabetes mellitus: from its molecular mechanisms to clinical practice","volume":"47","author":"Cho","year":"2023","journal-title":"Diabetes Metab J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v15.i5.576","article-title":"Pembrolizumab autoimmune related diabetes: moving forward, keep learning","volume":"15","author":"Garcia","year":"2024","journal-title":"World J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.3104","article-title":"Identification of immune checkpoint inhibitor-induced diabetes","volume":"10","author":"Ruiz-Esteves","year":"2024","journal-title":"JAMA Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2018.10.040","article-title":"Diabetic ketoacidosis induced by a single dose of pembrolizumab","volume":"37","author":"Maamari","year":"2019","journal-title":"Am J Emerg Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1530\/eje-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101473","article-title":"Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus","volume":"24","author":"Liu","year":"2022","journal-title":"Transl Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v14.i11.535","article-title":"Autoimmune diabetes from pembrolizumab: a case report and review of literature","volume":"14","author":"Bhanderi","year":"2023","journal-title":"World J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00423","article-title":"Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes","volume":"104","author":"Tsang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241241493","article-title":"Pembrolizumab induced type 1 diabetes mellitus in a patient with metastatic melanoma and literature review on steroids as a treatment option","volume":"30","author":"Greene","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2020-0054","article-title":"Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus","volume":"20","author":"Kyriacou","year":"2020","journal-title":"Clin Med (Lond)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13888","article-title":"Exploring the progress and trends of immunotherapy for type 1 diabetes: a comprehensive bibliometric analysis spanning nearly two decades","volume":"26","author":"Jiang","year":"2025","journal-title":"Obes Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.09.040","article-title":"Pdl1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-\u03b1 and-\u0393 via Irf1 induction","volume":"36","author":"Colli","year":"2018","journal-title":"EBioMedicine"},{"key":"B19","doi-asserted-by":"publisher","first-page":"8295","DOI":"10.1038\/s41598-018-26471-9","article-title":"Interferon-gamma drives programmed death-ligand 1 expression on islet \u03b2 cells to limit T cell function during autoimmune diabetes","volume":"8","author":"Osum","year":"2018","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: Esmo clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: Asco guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1689-1","article-title":"Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report","volume":"64","author":"Martin-Liberal","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.21037\/acr-24-159","article-title":"Case report: Pembrolizumab-induced acute type 1 diabetes mellitus and diabetic ketoacidosis in a perioperative esophageal squamous cell carcinoma patient","volume":"9","author":"Xiong","year":"2025","journal-title":"AME Case Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0740","article-title":"Anti-Pd-1 therapy-associated type 1 diabetes in a pediatric patient with relapsed classical Hodgkin lymphoma","volume":"43","author":"Samoa","year":"2020","journal-title":"Diabetes Care"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1835-4","article-title":"A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome","volume":"65","author":"Hansen","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0222","article-title":"A case of pembrolizumab-induced fulminant type 1 diabetes mellitus in breast cancer","volume":"13","author":"Tang","year":"2021","journal-title":"Immunotherapy"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.12659\/ajcr.931702","article-title":"A severe case of diabetic ketoacidosis and new-onset type 1 diabetes mellitus associated with anti-glutamic acid decarboxylase antibodies following immunotherapy with pembrolizumab","volume":"22","author":"Kedzior","year":"2021","journal-title":"Am J Case Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00262-016-1913-7","article-title":"A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes","volume":"66","author":"Chae","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000012907","article-title":"Anti-Pd-1 pembrolizumab induced autoimmune diabetes in Chinese patient: a case report","volume":"97","author":"Li","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.endien.2022.06.013","article-title":"Abrupt-onset diabetes mellitus secondary to pembrolizumab","volume":"70","author":"Pastor Alcaraz","year":"2023","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.35276","article-title":"A case of pembrolizumab-induced diabetic ketoacidosis and hyperthyroidism in a patient with recurrent esophageal adenocarcinoma","volume":"15","author":"Salangsang","year":"2023","journal-title":"Cureus"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-025-00795-0","article-title":"Immune checkpoint inhibitor-related type 1 diabetes mellitus with closely monitored dynamics of glutamic acid decarboxylase antibody levels before and after disease onset","volume":"16","author":"Sakaue","year":"2025","journal-title":"Diabetol Int"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00014","article-title":"Immune checkpoint inhibitor-induced diabetic ketoacidosis: a report of four cases and literature review","volume":"11","author":"Hong","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8781347","article-title":"Immune checkpoint inhibitor induced diabetes mellitus treated with insulin and metformin: evolution of diabetes management in the era of immunotherapy","volume":"2019","author":"Alrifai","year":"2019","journal-title":"Case Rep Oncol Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.76687","article-title":"Fulminant type 1 diabetes mellitus leading to diabetic ketoacidosis and mesenteric ischemia with necrosis following pembrolizumab administration: a case report","volume":"16","author":"Ueki","year":"2024","journal-title":"Cureus"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13302","article-title":"Diabetic ketoacidosis secondary to new onset type 1 diabetes mellitus related to pembrolizumab therapy","volume":"13","author":"Hernandez","year":"2021","journal-title":"Cureus"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4045\/tidsskr.18.0597","article-title":"Diabetic ketoacidosis following immunotherapy for lung cancer","volume":"139","author":"Skorpen","year":"2019","journal-title":"Tidsskr Nor Laegeforen"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.92247","article-title":"Immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with melanoma: a case report","volume":"17","author":"Shavit","year":"2025","journal-title":"Cureus"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e245846","DOI":"10.1136\/bcr-2021-245846","article-title":"Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab","volume":"15","author":"Zand Irani","year":"2022","journal-title":"BMJ Case Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-217454","article-title":"Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma","volume":"2016","author":"Aleksova","year":"2016","journal-title":"BMJ Case Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2019.100849","article-title":"Fulminant type 1 diabetes mellitus induced by pembrolizumab in a patient with urothelial carcinoma: a case report","volume":"24","author":"Tohi","year":"2019","journal-title":"Urol Case Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-018-1234-8","article-title":"Diabetes mellitus induced by Pd-1 and Pd-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype","volume":"56","author":"Marchand","year":"2019","journal-title":"Acta Diabetol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2217\/imt-2017-0042","article-title":"Case report: Pembrolizumab-induced type 1 diabetes in a patient with metastatic cholangiocarcinoma","volume":"9","author":"Smith-Cohn","year":"2017","journal-title":"Immunotherapy"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13065","article-title":"Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: a case report","volume":"10","author":"Edahiro","year":"2019","journal-title":"Thorac Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/mjt.0000000000001681","article-title":"Immune-mediated diabetes mellitus, diabetic ketoacidosis, enteritis, and thrombotic thrombocytopenic purpura presenting as adverse effects of pembrolizumab therapy","volume":"31","author":"Luong","year":"2024","journal-title":"Am J Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000030398","article-title":"Type 1 diabetes associated with immune checkpoint inhibitors for Malignant melanoma: a case report and review of 8 cases","volume":"101","author":"Ishiguro","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.65906","article-title":"Pembrolizumab-induced ketoacidosis: a case report","volume":"16","author":"Guimar\u00e3es","year":"2024","journal-title":"Cureus"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18983","article-title":"Pembrolizumab-induced diabetic ketoacidosis: a review of critical care case","volume":"13","author":"Sankar","year":"2021","journal-title":"Cureus"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.80083","article-title":"Onset of type 1 diabetes mellitus five months after pembrolizumab therapy for nodular melanoma: a case report","volume":"17","author":"Sanji","year":"2025","journal-title":"Cureus"},{"key":"B50","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1186\/s13256-023-04106-6","article-title":"Metachronous immune-related adverse events involving type 1 diabetes and isolated adrenocorticotropic hormone deficiency associated with pembrolizumab monotherapy for metastatic head and neck cancer: a case report","volume":"17","author":"Iijima","year":"2023","journal-title":"J Med Case Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14736","article-title":"Late-onset acute type 1 diabetes mellitus 7\u2009months after discontinuation of pembrolizumab against lung cancer","volume":"14","author":"Ichihara","year":"2023","journal-title":"Thorac Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14340","article-title":"Rapid onset type 1 diabetes associated with the programmed cell death-1 inhibitor pembrolizumab","volume":"49","author":"Boyle","year":"2019","journal-title":"Intern Med J"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241255699","article-title":"Pembrolizumab-induced type 1 diabetes","volume":"30","author":"Maia","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.84880","article-title":"Pembrolizumab-induced hypothyroidism and diabetes mellitus: A rare case presentation post-treatment","volume":"17","author":"Perera","year":"2025","journal-title":"Cureus"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220921543","article-title":"Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab","volume":"27","author":"Kethireddy","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1177\/03000605221121940","article-title":"Type 1 diabetes mellitus induced by Pd-1 inhibitors in China: A report of two cases","volume":"50","author":"Luo","year":"2022","journal-title":"J Int Med Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/eje-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: An Ese clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aec9029","article-title":"Beta cell-targeted Pd-1 agonist inhibits cell-mediated autoimmunity in pancreas tissue slices","volume":"12","author":"Becker","year":"2026","journal-title":"Sci Adv"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1679751","article-title":"Immune checkpoint inhibitor-associated diabetes mellitus: Mechanisms, clinical manifestations, and management strategies","volume":"16","author":"Chen","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-091708","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events: A retrospective study from Vigibase update in 2024 looking for emergent safety signals","volume":"14","author":"L'Orphelin","year":"2024","journal-title":"BMJ Open"},{"key":"B62","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1947327\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:26:23Z","timestamp":1788236783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1947327\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":62,"alternative-id":["10.3389\/fendo.2026.1947327"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1947327","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1947327"}}